coronavirus pandemic mental health impact covid cell in head bre

(© DonkeyWorx - stock.adobe.com)

“Our evidence suggests that it’s not the virus itself that causes the damage, but a unique population of T cells, which are part of the immune system, that are actually responsible for the damage,” says study lead author Elizabeth Balint, a doctoral student at McMaster University, in a media release.

McMaster researchers concentrated their efforts on understanding the Zika virus’s effects. Their findings revealed the presence of T cells specifically targeting Zika, aiming to eliminate cells infected by the virus. However, the study also uncovered a surprising element: a specific subset of T cells, identified as NKG2D+CD8+ T cells, which behaved abnormally by attacking cells not infected by Zika. These aggressive T cells were pinpointed as the cause of neurological damage not only from Zika but also from other severe infections like COVID-19 and septic shock.

The harmful impact of these T cells is linked to their production of large quantities of cytokines, proteins that normally help manage the body’s immune response by guiding immune cells to the site of infection or injury. However, an overproduction of these cytokines can lead to an excessive activation of the immune system, resulting in “collateral damage.”

Immune system: Army Men Fight COVID
While scientists have believed that viruses like COVID-19 could cause debilitating cognitive impairments, a new study reveals the body’s immune response is the actual culprit. (© Ezume Images – stock.adobe.com)

“If our body’s immune cells overreact and over produce inflammatory cytokines, this condition will lead to non-specific activation of our immune cells which in turn leads to collateral damage,” explains Ali Ashkar, a professor with the Department of Medicine and the Canada Research Chair in Natural Immunity and NK Cell Function. “This can have severe consequences if it happens in the brain.”

This discovery opens new avenues for developing treatments for neurological conditions triggered by acute viral infections. Researchers have already identified a promising treatment using an antibody that can block and treat neurotoxicity in animal models. This antibody is currently undergoing clinical trials for other applications in humans, offering hope for future therapeutic interventions.

Balint is optimistic about the potential of this research to lead to effective treatments for humans. She plans to extend the study to other viruses, aiming to devise the most effective treatment strategies.

“There are a few different other viruses we’re interested in studying, which will aid us in creating the best treatment options,” says Balint.

The study was supported by the Canadian Institutes of Health Research, with Balint being a recipient of a Canada Graduate Scholarship Doctoral Award.

The study is published in the journal Nature Communications.

About StudyFinds Staff

StudyFinds sets out to find new research that speaks to mass audiences — without all the scientific jargon. The stories we publish are digestible, summarized versions of research that are intended to inform the reader as well as stir civil, educated debate. StudyFinds Staff articles are AI assisted, but always thoroughly reviewed and edited by a Study Finds staff member. Read our AI Policy for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

Chris Melore

Editor

Sophia Naughton

Associate Editor